pyrazines has been researched along with Multiple Primary Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Dun, XY; Hou, J; Li, YH; Yuan, ZG | 1 |
| Akahane, D; Gotoh, M; Kitahara, T; Ohyashiki, K; Sakuta, J | 1 |
| Hasegawa, S; Hashimoto, M; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H | 1 |
4 other study(ies) available for pyrazines and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines; Remission Induction | 2009 |
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Hyperlipidemias; Lipoma; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines | 2010 |
Curative resection of double primary lung cancer after 15-month bortezomib administration.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pneumonectomy; Pyrazines; Treatment Outcome | 2012 |